阿替利珠单抗联合贝伐珠单抗对比舒尼替尼治疗伴肉瘤样特征的初治转移性肾细胞癌:IMmotion151试验预设亚组分析
IMmotion151试验预设亚组分析纳入伴肉瘤样特征的初治晚期或转移性肾细胞癌患者,随机接受阿替利珠单抗联合贝伐珠单抗(n=68)或舒尼替尼(n=74)。联合组中位无进展生存期显著延长(8.3 vs 5.3个月;HR 0.52,95%CI 0.34-0.79),客观缓解率更高(49% vs 14%),安全性符合已知特征。
要点
- 阿替利珠单抗联合贝伐珠单抗较舒尼替尼显著延长伴肉瘤样特征肾癌患者的中位无进展生存期(8.3 vs 5.3个月;HR 0.52)。
- 联合组客观缓解率49% vs 14%,完全缓解率10% vs 3%,症状改善更明显。
- PD-L1阳性亚组中位无进展生存期8.6 vs 5.6个月(HR 0.45,95%CI 0.26-0.77)。
核心结论
- 在伴肉瘤样特征的初治转移性肾细胞癌患者中,阿替利珠单抗联合贝伐珠单抗较舒尼替尼显著延长无进展生存期并提高缓解率。
研究设计与样本
- IMmotion151随机III期试验的预设亚组分析,纳入伴任何肉瘤样特征成分的初治晚期或转移性肾细胞癌患者,联合组68例,舒尼替尼组74例。
主要发现
- 联合组中位无进展生存期8.3个月 vs 舒尼替尼组5.3个月(HR 0.52,95%CI 0.34-0.79)。
- PD-L1阳性肿瘤患者中位无进展生存期8.6 vs 5.6个月(HR 0.45,95%CI 0.26-0.77)。
- 联合组客观缓解率49% vs 14%,完全缓解率10% vs 3%。
- 联合组报告的症状改善优于舒尼替尼组。
- 安全性与该药已知特征及IMmotion151总体安全性人群一致。
临床怎么用
- 对于伴肉瘤样特征的初治转移性肾细胞癌患者,可考虑阿替利珠单抗联合贝伐珠单抗作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with metastatic renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and have shown limited responsiveness to inhibition of the VEGF pathway. We conducted a prespecified analysis of the randomised, phase 3 IMmotion151 trial in previously untreated patients with advanced or metastatic RCC to assess the effectiveness of atezolizumab + bevacizumab versus sunitinib in a subgroup of patients with sarcomatoid features. Patients whose tumour had any component of sarcomatoid features were included and received atezolizumab + bevacizumab (n = 68) or sunitinib (n = 74). Baseline characteristics were similar between the groups. Median progression-free survival was significantly longer in the group receiving atezolizumab + bevacizumab overall (8.3 vs 5.3 mo; hazard ratio [HR] 0.52 95% confidence interval [CI] 0.34-0.79) and in the subset of patients with PD-L1-positive tumours (8.6 vs 5.6 mo; HR 0.45, 95% CI 0.26-0.77). More patients receiving atezolizumab + bevacizumab achieved an objective response (49% vs 14%), including complete responses (10% vs 3%), and reported greater symptom improvements versus sunitinib. Safety was consistent with the known profiles of each drug and with that reported in the overall safety-evaluable population of IMmotion151. This analysis supports enhanced activity of atezolizumab + bevacizumab in patients with sRCC. PATIENT SUMMARY: In this report, we looked at patients with a specific type of kidney cancer (tumours with sarcomatoid features) that has been hard to treat. A treatment with two drugs (atezolizumab and bevacizumab) appeared to help patients live longer without the disease getting worse than another drug (sunitinib) that is often used. Patients who took the two drugs also said they were better able to carry out their everyday activities than patients who took sunitinib. The combination of these two drugs may work better in patients with this type of advanced kidney cancer.
引用
- Rini BI, Motzer RJ, Powles T, et al. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. Eur Urol. 2020. PMID: 32654802. doi:10.1016/j.eururo.2020.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。